to study the effect of calcium and vitamin D supplementation in children with leukemia
Phase 3
Recruiting
- Conditions
- leukemia.Acute lymphoblastic leukemia [ALL]
- Registration Number
- IRCT20150119020715N7
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 66
Inclusion Criteria
All of the children with acute lymphoblastic leukemia above 5 years old
Exclusion Criteria
Patients with no compliance with using supplements
Patients with no satisfaction to continue the study
No compliance with enteric use of supplements
Not doing bone marrow densitometry
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bone mineral density. Timepoint: in the beginning of the study (before the intervention) and 6 months after the intervention. Method of measurement: Bone Mineral Densitometry.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie calcium and vitamin D3's impact on bone mineral density in ALL patients?
How does calcium-vitamin D3 supplementation compare to bisphosphonates in managing osteopenia in pediatric leukemia?
Which biomarkers correlate with improved bone health outcomes in ALL patients receiving calcium and vitamin D3?
What are the potential adverse events associated with long-term calcium and vitamin D3 use in ALL pediatric trials?
Are there combination therapies involving calcium, vitamin D3, and anti-cancer agents for ALL bone protection?